Product Information
VALACYCLOVIR HCL 500 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.2289 per EA under NDC 00904656507. Its NADAC has been published 470 times since Oct 4, 2017.
FDA first approved this application on May 24, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Valacyclovir Hydrochloride market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
500 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904656507
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
VALACYCLOVIR HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090682FDA Approved
5/24/2010
TE Code
AB
On Market Since
5/24/2010
Pharmacological Classes
Price Statistics
The NADAC for VALACYCLOVIR HCL 500 MG TABLET has been published 470 times since Oct 4, 2017, and over the history we have for it it has declined 26.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2289 per EA |
|---|---|
| All-time high | $0.3284 (Aug 14, 2019) |
| All-time low | $0.2043 (Nov 20, 2024) |
| 52-week high | $0.2349 |
| 52-week low | $0.2228 |
| Median price | $0.2813 |
| Average price | $0.2766 |
| Largest weekly change | -22.3% (Nov 20, 2024) |
| Weeks tracked | 470 |
| Tracking since | Oct 4, 2017 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Valacyclovir Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VALACYCLOVIR HCL 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VALACYCLOVIR HCL 500 MG TABLET, manufactured by Major Pharmaceuticals, is $0.2289 per EA (NDC 00904656507), effective Sep 30, 2026.
How has the price of VALACYCLOVIR HCL 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for VALACYCLOVIR HCL 500 MG TABLET has declined 26.6%. It has been tracked across 470 weekly CMS publications since Oct 4, 2017.
What are the highest and lowest recorded NADAC prices for VALACYCLOVIR HCL 500 MG TABLET?
Since Oct 4, 2017, the NADAC for VALACYCLOVIR HCL 500 MG TABLET has ranged from a low of $0.2043 (Nov 20, 2024) to a high of $0.3284 (Aug 14, 2019), with a median of $0.2813 per EA.
Are there cheaper alternatives to VALACYCLOVIR HCL 500 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as VALACYCLOVIR HCL 500 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures VALACYCLOVIR HCL 500 MG TABLET?
VALACYCLOVIR HCL 500 MG TABLET (NDC 00904656507) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.